Cal­i­for­nia takes an­oth­er step for­ward in its in­sulin pro­duc­tion with $50M in­vest­ment

The state of Cal­i­for­nia an­nounced last year that it was go­ing to make in­roads in pro­duc­ing its own in­sulin and low­er­ing the price, and an­oth­er step for­ward in that plan has been tak­en.

Over the week­end, the Cal­i­for­nia gov­er­nor’s of­fice an­nounced that the state has se­cured a con­tract with the man­u­fac­tur­er Civi­ca to make the state’s af­ford­able in­sulin. Ac­cord­ing to a re­lease from Civi­ca, it plans to pro­duce biosim­i­lar ver­sions of both long and short-term in­sulins. Specif­i­cal­ly, Civi­ca will make the prod­ucts glargine, lispro and as­part which are ex­pect­ed to be in­ter­change­able with Lan­tus, Hu­ma­log and No­voLog, re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER